S.C. Ropharma S.A.

BVB:RPH Stock Report

Market Cap: RON 111.5m

S.C. Ropharma Balance Sheet Health

Financial Health criteria checks 6/6

S.C. Ropharma has a total shareholder equity of RON266.8M and total debt of RON75.7M, which brings its debt-to-equity ratio to 28.4%. Its total assets and total liabilities are RON1.0B and RON773.5M respectively. S.C. Ropharma's EBIT is RON25.3M making its interest coverage ratio 5.2. It has cash and short-term investments of RON28.8M.

Key information

28.38%

Debt to equity ratio

RON 75.71m

Debt

Interest coverage ratio5.2x
CashRON 28.81m
EquityRON 266.82m
Total liabilitiesRON 773.47m
Total assetsRON 1.04b

Recent financial health updates

Recent updates

Analysis Article Dec 06

S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
Analysis Article Dec 09

Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On Capital

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article Sep 23

S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of Return

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article Jun 01

Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Mar 16

Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Analysis Article May 15

S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Mar 26

S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital Effectively

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article Dec 23

Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Analysis Article Nov 24

We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...

Financial Position Analysis

Short Term Liabilities: RPH's short term assets (RON683.1M) exceed its short term liabilities (RON657.5M).

Long Term Liabilities: RPH's short term assets (RON683.1M) exceed its long term liabilities (RON116.0M).


Debt to Equity History and Analysis

Debt Level: RPH's net debt to equity ratio (17.6%) is considered satisfactory.

Reducing Debt: RPH's debt to equity ratio has reduced from 42% to 28.4% over the past 5 years.

Debt Coverage: RPH's debt is well covered by operating cash flow (62.4%).

Interest Coverage: RPH's interest payments on its debt are well covered by EBIT (5.2x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/20 23:16
End of Day Share Price 2026/08/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

S.C. Ropharma S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.